伊马替尼治疗慢性粒细胞白血病致胸腔积液1例(2)
 |
| 第1页 |
参见附件。
因此，CML患者在服用格列卫期间，需要监测血压、血清胆固醇水平，定期复查胸片，一旦出现胸闷、气促、胸痛等症状立即就诊，排除其他继发性因素后考虑药物所致者应立即停药，并予利尿剂或糖皮质激素治疗。
[参考文献]
[1] Stephens J，Carpiuc KT，Botteman M. The burden of managing pleural effusions in patientswith chronic myelogenous leukemia post-imatinibfailure：a literature-based economic analysis [J]. Int J Gen Med，2010，3：31-36.
[2] Wei G，Rafiyath S，Liu D. First-line treatment for chronic myeloid leukemia：dasatinib，nilotinib，or imatinib [J]. J Hematol Oncol，2010，3：47-56.
[3] Lavallade H，Punnialingam S，Milojkovic D，et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis [J]. Br J Haematol，2008，141(5)：745-747.
[4] Yamasawa H，Sugiyama Y，Bando M，et al. Drug-induced pneumonitis associated with Imatinib Mesylate in a patient with idiopathic pulmonary fibrosis [J]. Respiration，2008，75(3)：350-354.
[5] Bergeron A，Rea D，Levy V，et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia：a case series [J]. Am J Respir Crit Care Med，2007，176(8)：814-818.
[6] Quintas Cardama A，Kantarjian H，O'brien S，et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure [J]. J Clin Oncol，2007，25(25)：3908-3914.
[7] Masiello D，Gorospe G，Yang AS. The occurrence and management of fluid retention associated with TKI therapy in CML，with a focus on dasatinib [J]. J Hematol Oncol，2009，2：46.
(收稿日期：2011-09-14 本文编辑：张瑜杰)
您现在查看是摘要介绍页，详见PDF附件(2390kb)。